MCID: PPL018
MIFTS: 46

Papillary Adenocarcinoma malady

Categories: Cancer diseases

Aliases & Classifications for Papillary Adenocarcinoma

Aliases & Descriptions for Papillary Adenocarcinoma:

Name: Papillary Adenocarcinoma 12 14 69
Infiltrating and Papillary Adenocarcinoma 12
Infiltrating Papillary Adenocarcinoma 12
Papillary Adenocarcinoma Nos 12
Adenocarcinoma, Papillary 42
Adenocarcinoma Papillary 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3112
MeSH 42 D000231
NCIt 47 C2853 C7438

Summaries for Papillary Adenocarcinoma

Disease Ontology : 12 An adenocarcinoma that derives from epithelial cells originating in glandular tissue, which form complex papillary structures and exhibit compressive, destructive growth that replaces the normal tissue.

MalaCards based summary : Papillary Adenocarcinoma, also known as infiltrating and papillary adenocarcinoma, is related to fallopian tube papillary adenocarcinoma and papilloma. An important gene associated with Papillary Adenocarcinoma is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Adhesion and Signaling by ERBB4. The drugs Sunitinib and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include thyroid, lung and cervix, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 71 Papillary adenocarcinoma is a histological form of lung cancer that is diagnosed when the malignant... more...

Related Diseases for Papillary Adenocarcinoma

Diseases related to Papillary Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 219)
id Related Disease Score Top Affiliating Genes
1 fallopian tube papillary adenocarcinoma 32.8 KEAP1 NFE2L2
2 papilloma 29.9 MUC1 PGR
3 inverted papilloma 29.6 ERBB2 NKX2-1 VIM
4 sclerosing hemangioma 29.1 CDH1 ERBB2 MUC1 MUC2 PGR
5 aggressive digital papillary adenocarcinoma 12.3
6 lung papillary adenocarcinoma 12.0
7 peritoneal serous papillary adenocarcinoma 12.0
8 eccrine papillary adenocarcinoma 11.9
9 gastric papillary adenocarcinoma 11.9
10 papillary serous adenocarcinoma 10.9
11 nasopharyngeal carcinoma, 3 10.9
12 adenocarcinoma 10.8
13 thyroiditis 10.4
14 bronchogenic lung adenocarcinoma 10.3 CEACAM5 MUC1
15 immunodeficiency due to a classical component pathway complement deficiency 10.3 MUC1 VIM
16 autosomal recessive stickler syndrome 10.3 MUC1 VIM
17 lymphoplasmacyte-rich meningioma 10.3 CEACAM5 PGR
18 lymphomatous thyroiditis 10.3 PGR VIM
19 exotropia 10.3 MUC1 PGR
20 pulmonary artery choriocarcinoma 10.3 CEACAM5 ERBB2
21 mouth disease 10.3 ERBB2 PGR
22 adult endodermal sinus tumor 10.3 PGR VIM
23 glioma 10.3 ERBB2 PGR
24 mucoepidermoid thyroid carcinoma 10.3 ERBB2 PGR
25 triple-receptor negative breast cancer 10.2 ERBB2 PGR
26 histiocytic and dendritic cell cancer 10.2 ERBB2 PGR
27 biemond syndrome 10.2 PGR VIM
28 ovarian squamous cell carcinoma 10.2 CDH1 VIM
29 her2-receptor negative breast cancer 10.2 ERBB2 PGR
30 vulvar angiokeratoma 10.2 CEACAM5 MUC1 VIM
31 liver angiosarcoma 10.2 PGR VIM
32 glossopharyngeal motor neuropathy 10.2 CDH1 ERBB2
33 avian influenza 10.2 MUC1 NKX2-1 VIM
34 nervous system hibernoma 10.2 ERBB2 PGR
35 larynx verrucous carcinoma 10.2 CDH1 VIM
36 marfanoid hypermobility syndrome 10.2 MUC1 PGR VIM
37 diphallia 10.2 CDH1 ERBB2
38 gestational ovarian choriocarcinoma 10.2 MUC1 MUC2
39 chondroblastoma 10.2 MUC1 NKX2-1 VIM
40 endometrial stromal sarcoma 10.2 MUC1 PGR VIM
41 malignant epithelial mesothelioma 10.2 CDH1 MUC1
42 bladder adenocarcinoma 10.2 MUC1 PGR VIM
43 congenital muscular dystrophy with hyperlaxity 10.2 MUC1 NKX2-1 VIM
44 lacrimal gland mucoepidermoid carcinoma 10.2 CEACAM5 MUC1 PGR
45 breast pericanalicular fibroadenoma 10.2 NKX2-1 PGR
46 main bronchus cancer 10.2 CEACAM5 PGR
47 urinary system disease 10.2 MUC1 MUC2
48 sebaceous adenoma 10.2 MUC1 PGR VIM
49 uterine hypoplasia 10.2 PGR VIM
50 testicular granulosa cell tumor 10.2 MUC1 VIM

Graphical network of the top 20 diseases related to Papillary Adenocarcinoma:



Diseases related to Papillary Adenocarcinoma

Symptoms & Phenotypes for Papillary Adenocarcinoma

MGI Mouse Phenotypes related to Papillary Adenocarcinoma:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.95 NKX2-1 PGR VIM CDH1 ERBB2 MUC2
2 homeostasis/metabolism MP:0005376 9.91 CDH1 ERBB2 KEAP1 MUC2 NFE2L2 NKX2-1
3 digestive/alimentary MP:0005381 9.85 CDH1 ERBB2 KEAP1 MUC2 NFE2L2 NKX2-1
4 mortality/aging MP:0010768 9.81 CDH1 ERBB2 FGF3 KEAP1 MUC2 NFE2L2
5 embryo MP:0005380 9.8 CDH1 ERBB2 FGF3 NFE2L2 PGR VIM
6 neoplasm MP:0002006 9.43 NKX2-1 PGR CDH1 ERBB2 MUC2 NFE2L2
7 normal MP:0002873 9.17 CDH1 ERBB2 FGF3 NFE2L2 NKX2-1 PGR

Drugs & Therapeutics for Papillary Adenocarcinoma

Drugs for Papillary Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sunitinib Approved, Investigational Phase 3,Phase 2 341031-54-7, 557795-19-4 5329102
2
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 1,Phase 2 33069-62-4 36314
4
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
7
Sorafenib Approved, Investigational Phase 3,Phase 2,Phase 1 284461-73-0 216239 406563
8
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
9
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
12
Epirubicin Approved Phase 3 56420-45-2 41867
13
Pancrelipase Approved Phase 3,Phase 2,Phase 1,Early Phase 1 53608-75-6
14
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
15
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
16
Doxil Approved June 1999 Phase 3,Phase 2 31703
17 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
18 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
19 pancreatin Phase 3,Phase 2,Phase 1,Early Phase 1
20 pancreatic polypeptide Phase 3,Phase 1
21
Erlotinib Hydrochloride Phase 3,Phase 2 183319-69-9 176871
22 Analgesics Phase 3
23 Adjuvants, Anesthesia Phase 3
24 Narcotics Phase 3
25 Albumin-Bound Paclitaxel Phase 3,Phase 1,Phase 2
26 Topoisomerase Inhibitors Phase 3,Phase 2
27 Analgesics, Opioid Phase 3
28 Anesthetics Phase 3,Phase 2
29 Anesthetics, General Phase 3
30 Anesthetics, Intravenous Phase 3
31 Peripheral Nervous System Agents Phase 3,Phase 2
32 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1
34 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
35 Protein Kinase Inhibitors Phase 3,Phase 1,Phase 2
36 Antifungal Agents Phase 3,Phase 2,Phase 1
37 Liver Extracts Phase 3,Phase 2,Phase 1
38 Antimetabolites Phase 3,Phase 2,Phase 1
39 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
40 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
41 Antimitotic Agents Phase 3,Phase 1,Phase 2
42 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
43 Antiviral Agents Phase 3,Phase 2,Phase 1
44 Central Nervous System Depressants Phase 3,Phase 2
45 Cola Nutraceutical Phase 3,Phase 1
46
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
47
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
48
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
49
Etoposide Approved Phase 2 33419-42-0 36462
50
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941

Interventional clinical trials:

(show top 50) (show all 133)
id Name Status NCT ID Phase
1 Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Endometrial Cancer Completed NCT00005583 Phase 3
2 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
3 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
5 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
6 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3
7 Sorafenib in Treating Patients at Risk of Relapse After Undergoing Surgery to Remove Kidney Cancer Completed NCT00492258 Phase 3
8 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
9 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
10 Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer Active, not recruiting NCT01672892 Phase 3
11 S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Active, not recruiting NCT01120249 Phase 3
12 Savolitinib vs. Sunitinib in MET-driven PRCC Not yet recruiting NCT03091192 Phase 3
13 Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer Unknown status NCT00541008 Phase 2
14 RAPTOR: RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Tumors Program in Europe Completed NCT00688753 Phase 2
15 Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 Completed NCT00085293 Phase 2
16 Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine Completed NCT00098813 Phase 2
17 Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00104871 Phase 2
18 Sutent Adjunctive Treatment of Differentiated Thyroid Cancer Completed NCT00668811 Phase 2
19 Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma Completed NCT00506779 Phase 1, Phase 2
20 A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC) Completed NCT00726323 Phase 2
21 Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer Completed NCT00060307 Phase 2
22 Papillary Serous Carcinoma of the Endometrium Completed NCT00515073 Phase 2
23 A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2
24 Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy Completed NCT00729157 Phase 2
25 Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid Cancer Completed NCT01502410 Phase 2
26 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2
27 Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer Completed NCT00118248 Phase 2
28 Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer Completed NCT00459875 Phase 2
29 Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer Completed NCT01005329 Phase 2
30 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2
31 RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe Completed NCT00688623 Phase 2
32 Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer Completed NCT00519896 Phase 2
33 A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H... Completed NCT00923481 Phase 2
34 Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer Completed NCT00134043 Phase 2
35 pazopanib_NCRCC,Ph2 STUDY Completed NCT01538238 Phase 2
36 Study to Evaluate Safety and Biological Activity of TroVax® Vaccine Given in Conjunction With IL-2 to Treat Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT00325507 Phase 2
37 Bortezomib in Treating Patients With Metastatic Kidney Cancer Completed NCT00276614 Phase 2
38 Ridaforolimus in Treating Patients With Recurrent Metastatic and/or Locally Advanced Endometrial Cancer Completed NCT00770185 Phase 2
39 Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer Completed NCT00401128 Phase 2
40 Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery Completed NCT00459979 Phase 2
41 Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer Completed NCT00027573 Phase 2
42 Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Completed NCT00126503 Phase 1, Phase 2
43 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma Completed NCT01108445 Phase 2
44 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors Completed NCT00335556 Phase 2
45 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2
46 Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer Completed NCT00465179 Phase 2
47 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2
48 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
49 Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT02101775 Phase 2
50 MEDI4736 Combinations in Metastatic Renal Cell Carcinoma Recruiting NCT02819596 Phase 1, Phase 2

Search NIH Clinical Center for Papillary Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma, papillary

Genetic Tests for Papillary Adenocarcinoma

Anatomical Context for Papillary Adenocarcinoma

MalaCards organs/tissues related to Papillary Adenocarcinoma:

39
Thyroid, Lung, Cervix, Ovary, Lymph Node, Pancreas, Salivary Gland

Publications for Papillary Adenocarcinoma

Articles related to Papillary Adenocarcinoma:

(show top 50) (show all 340)
id Title Authors Year
1
Low-grade nasopharyngeal papillary adenocarcinoma: a case report and review of the literature. ( 27274289 )
2016
2
Aggressive papillary adenocarcinoma on atypical localization: A unique case report. ( 27428196 )
2016
3
Papillary adenocarcinoma of the renal pelvis with renal calculus: A rare case report. ( 27123287 )
2016
4
Treatment of endolymphatic sac tumour (Papillary adenocarcinoma) of the temporal bone. ( 27330425 )
2016
5
Villoglandular papillary adenocarcinoma of the uterine cervix: A report of 4 cases and a review of the literature. ( 26870293 )
2016
6
Clinicopathological Features of Low-Grade Thyroid-Like Nasopharyngeal Papillary Adenocarcinoma. ( 27384157 )
2016
7
Papillary adnexal neoplasm (Aggressive digital papillary adenocarcinoma) on the ankle of a 15 year old girl: case report and review of literature from a pediatric perspective. ( 27535353 )
2016
8
Papillary adenocarcinoma with tentacular processes (with video). ( 27302875 )
2016
9
A retrospective review of 11 cases of villoglandular papillary adenocarcinoma of the uterine cervix and a review of the literature. ( 26998142 )
2016
10
Metastatic Papillary Adenocarcinoma in a 22-Year-Old: Is Her History of Mayer-Rokitansky-KA1ster-Hauser Syndrome Causative or Incidental? ( 27987200 )
2016
11
Malignant transformation of alveolar adenoma to papillary adenocarcinoma: a case report. ( 27162700 )
2016
12
An unexpected digital papillary adenocarcinoma of the thumb. ( 27990456 )
2016
13
Aggressive Digital Papillary Adenocarcinoma With Multiple Organ Metastases: A Case Report and Review of the Literature. ( 27870729 )
2016
14
Low-grade papillary adenocarcinoma of nasopharynx with expression of thyroid transcription factor-1: Case report and review of literature. ( 27721286 )
2016
15
Role of Radiotherapy in Aggressive Digital Papillary Adenocarcinoma. ( 27098633 )
2016
16
Right visual loss due to choroidal metastasis of a papillary adenocarcinoma of the lung: a case report. ( 26662155 )
2015
17
Spreading Patterns, Prognostic factors and Treatment Outcomes of Nasopharyngeal Papillary Adenocarcinoma and Salivary Gland-type Carcinomas. ( 26118586 )
2015
18
Primary thyroid-like papillary adenocarcinoma of the nasal septum: a case report. ( 25651353 )
2015
19
Aggressive Digital Papillary Adenocarcinoma. ( 26576210 )
2015
20
Aggressive digital papillary adenocarcinoma - a rare malignant tumor of the sweat glands: two case reports and a review of the literature. ( 25848311 )
2015
21
"Apocrine Hidrocystoma and Cystadenoma"-like Tumor of the Digits or Toes: A Potential Diagnostic Pitfall of Digital Papillary Adenocarcinoma. ( 26523544 )
2015
22
Endoscopic ultrasonography-guided drainage of infected intracystic papillary adenocarcinoma of the liver. ( 26412329 )
2015
23
Next-generation sequencing reveals rare genomic alterations in aggressive digital papillary adenocarcinoma. ( 26386519 )
2015
24
Aggressive Digital Papillary Adenocarcinoma: Case Report of a Positive Sentinel Lymph Node and Discussion of Utility of Sentinel Lymph Node Biopsy. ( 25954845 )
2015
25
Digital Papillary Adenocarcinoma: Presentation, Natural History and Management. ( 26266016 )
2015
26
Low-grade papillary adenocarcinoma of minor salivary glands in pregnancy. ( 26960505 )
2015
27
Is endoscopic submucosal dissection safe for papillary adenocarcinoma of the stomach? ( 25852280 )
2015
28
Clinical significance of a papillary adenocarcinoma component in early gastric cancer: a single-center retrospective analysis of 628 surgically resected early gastric cancers. ( 25142800 )
2014
29
Aggressive Digital Papillary Adenocarcinoma-A rare Entity Posing a Diagnostic Challenge. ( 25977623 )
2014
30
Cystic intraductal papillary adenocarcinoma of the bile duct of the caudate lobe initially manifesting as a simple cyst on CT. ( 24682931 )
2014
31
A rare coexistence of villoglandular papillary adenocarcinoma of the uterine cervix and brenner tumor of the ovary. ( 24716032 )
2014
32
Papillary adenocarcinoma in situ of the skin: report of four cases. ( 24855569 )
2014
33
Clinicopathological features of gallbladder papillary adenocarcinoma. ( 25501049 )
2014
34
Magnetic Resonance Manifestations of Villoglandular Papillary Adenocarcinoma of the Uterine Cervix with a Fern-leaf-like Appearance. ( 24990463 )
2014
35
Is aggressive digital papillary adenocarcinoma really aggressive digital papillary adenocarcinoma? ( 25126455 )
2014
36
Intraductal dissemination of papillary adenocarcinoma of the ampulla of Vater in the pancreatic duct. ( 24471969 )
2014
37
Lung papillary adenocarcinoma complicated with paraneoplastic autoimmune hemolytic anemia: A case report. ( 26766978 )
2014
38
Primary serous papillary adenocarcinoma of the fallopian tube. ( 25163242 )
2014
39
Thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: Case report and literature review. ( 24893893 )
2014
40
A case report of a rare adnexal tumour: aggressive digital papillary adenocarcinoma. ( 24964471 )
2013
41
[A case of huge papillary adenocarcinoma of the gallbladder with marked necrosis]. ( 23303235 )
2013
42
Digital papillary adenocarcinoma: a tumour that should be considered in the differential diagnosis of neoplasms involving the digits. ( 23255030 )
2013
43
Metachronous pancreatic metastasis of an ovarian serous papillary adenocarcinoma after 8 years. ( 24294516 )
2013
44
Papillary adenocarcinoma of ciliary body. ( 24082678 )
2013
45
Surgical resection of cystic intraductal papillary adenocarcinoma of the bile duct: report of a case. ( 23832409 )
2013
46
Laparoscopic diagnosis of adenocarcinoma of the appendix mimicking serous papillary adenocarcinoma of the peritoneum. ( 24383020 )
2013
47
Villoglandular papillary adenocarcinoma of the cervix: a series of 28 cases including two with lymph node metastasis. ( 23552807 )
2013
48
Pathological implication and function of Bcl2-inhibitor of transcription in ovarian serous papillary adenocarcinomas. ( 23259782 )
2013
49
Thyroid-like papillary adenocarcinoma of the nasopharynx with focal thyroglobulin expression. ( 24018817 )
2013
50
Papillary eccrine adenoma should not be mistaken for aggressive digital papillary adenocarcinoma. ( 24274672 )
2013

Variations for Papillary Adenocarcinoma

Expression for Papillary Adenocarcinoma

Search GEO for disease gene expression data for Papillary Adenocarcinoma.

Pathways for Papillary Adenocarcinoma

GO Terms for Papillary Adenocarcinoma

Biological processes related to Papillary Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.46 ERBB2 NFE2L2 NKX2-1 VIM
2 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 8.96 MUC1 NFE2L2
3 proteasomal ubiquitin-independent protein catabolic process GO:0010499 8.62 KEAP1 NFE2L2

Sources for Papillary Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....